*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. While it regularly attracts the attention of competition authorities who apprehend, on the basis of anti-competitive practices law, certain deferred entry agreements or even acts of disparagement (see also Aut. conc., 16-D-01 of January 20, 2016 on practices referred to in Article L. 420-1 of the French Commercial Code implemented in the non-reimbursable drug distribution sector; Adde opinion 19-A-08 of April 14, 2019 relating to the sectors of distribution of medicines in towns and private medical biology,) the pharmaceutical sector is also of interest to the law of unfair practices, as illustrated by two recent rulings of the Cour de cassation. These
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.